Patrick Baeuerle - Feb 17, 2023 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Scientific Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Feb 17, 2023
Transactions value $
$0
Form type
4
Date filed
2/21/2023, 05:53 PM
Previous filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +38.5K +102.67% $0.00 76K Feb 17, 2023 Direct F1
holding CGEM Common Stock 341K Feb 17, 2023 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +77K $0.00 77K Feb 17, 2023 Common Stock 77K $11.34 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
F2 Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F3 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Remarks:

Exhibit 24.1 - Power of Attorney